Irisin Expression and Gene Polymorphism With Peripartum Cardiomyopathy.

NCT04927715 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2022-01-19

No results posted yet for this study

Summary

this is an observertional study aimed at Study the association between the level of irisin expression and (Fibronectin Type III Domain Containing 5 (FDNC5) gene polymorphism in female patients with peripartum cardiomyopathy.

Conditions

  • Peripartum Cardiomyopathy

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-20
Primary Completion
2022-01-30
Completion
2022-02-28

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04927715 on ClinicalTrials.gov